The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism.

Molecules · 2019 · PMC6600265 · PMID 31212694

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fell just short of statistical significanceno p-value reported

In Figure 3 F, while peritumoral CD3 + cells were increased in rosiglitazone treated mouse tumors, the increase fell just short of statistical significance.

also in 125 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.